

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Transcenta Holding Limited

創勝集團醫藥有限公司

(registered by way of continuation in the Cayman Islands with limited liability)

(Stock code: 6628)

DATE OF BOARD MEETING

The board of directors (the “**Board**”) of Transcenta Holding Limited (the “**Company**”, and its subsidiaries, the “**Group**”) hereby announces that a meeting of the Board of the Company will be held on Monday, March 30, 2026 for the purpose of considering and approving the annual results of the Group for the year ended December 31, 2025 and the recommendation of a final dividend, if any, and transacting any other business.

By Order of the Board
Transcenta Holding Limited
Xueming Qian
*Executive Director, Chairman and
Chief Executive Officer*

Hong Kong, March 18, 2026

As at the date of this announcement, the Board comprises Dr. Xueming Qian as executive director, chairman and chief executive officer, Dr. Li Xu as non-executive director and Mr. Jiasong Tang, Mr. Zhihua Zhang, Dr. Kumar Srinivasan and Ms. Helen Wei Chen as independent non-executive directors.